102,885 stock options granted to Veradermics (MANE) senior officer

Rhea-AI Filing Summary

Veradermics, Inc. reported that officer Mark Neumann, its Chief Commercial Officer and Strategy Officer, received a grant of stock options on February 3, 2026. The award covers 102,885 stock options with an exercise price of $17 per share.

According to the vesting terms, 25% of the underlying common shares vest on February 3, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. After this grant, Neumann directly holds 102,885 derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Neumann Mark

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	102,885	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 102,885 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neumann Mark

(Last) (First) (Middle)

C/O VERADERMICS, INCORPORATED

470 JAMES ST.

(Street)

NEW HAVEN CT 06513

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Commercial Officer		Strategy Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	02/03/2026		A		102,885		(1)	02/03/2036	Common Stock	102,885	$0	102,885	D

Explanation of Responses:

1. The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

Remarks:

	/s/ Michael Greco, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veradermics (MANE) report for Mark Neumann?

Veradermics reported a grant of stock options to officer Mark Neumann. He received 102,885 stock options on February 3, 2026, giving him the right to buy common shares at a $17 exercise price, subject to a multi-year vesting schedule tied to continued service.

How many Veradermics stock options were granted to Mark Neumann on February 3, 2026?

Mark Neumann was granted 102,885 Veradermics stock options. These options are derivative securities giving him the right to acquire an equal number of common shares at a fixed $17 exercise price, with vesting over time rather than all at once.

What is the exercise price of Mark Neumann’s Veradermics stock options?

The stock options granted to Mark Neumann have an exercise price of $17 per share. This means he can buy Veradermics common stock at $17 once portions of the 102,885-option grant vest under the stated vesting schedule, assuming his continued service.

What is the vesting schedule for Mark Neumann’s Veradermics option grant?

The option vests 25% of the underlying shares on February 3, 2027. The remaining 75% then vests in equal monthly installments over the next 36 months, and all vesting is conditioned on Neumann’s continued service with Veradermics during this period.

What position does Mark Neumann hold at Veradermics (MANE) in this Form 4?

In this Form 4, Mark Neumann is identified as an officer of Veradermics. His listed titles are Chief Commercial Officer and Strategy Officer, reflecting dual responsibilities in commercial leadership and strategic planning for the company’s business activities.

Are Mark Neumann’s Veradermics stock options held directly or indirectly?

Mark Neumann’s Veradermics stock options are reported as held directly. The Form 4 lists the ownership form for the 102,885 derivative securities as “D,” indicating direct ownership, with no additional nature-of-ownership entity specified in the filing excerpt.